Specimen Collection HEMATOLOGICAL MALIGNANCIES. CGI LABORATORIES 201 Route 17 North, 2nd Floor Rutherford, NJ SOLID TUMORS

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Specimen Collection HEMATOLOGICAL MALIGNANCIES. CGI LABORATORIES 201 Route 17 North, 2nd Floor Rutherford, NJ SOLID TUMORS"

Transcription

1 Specimen Collection Specimen Retrieval Kits 2 Sending your Specimens 2 Labeling Instructions 2 Handling of a Bone Marrow Specimen Dry Tap 3 CGI LABORATORIES 201 Route 17 North, 2nd Floor Rutherford, NJ Client Services: Tel: Toll Free: Fax: HEMATOLOGICAL MALIGNANCIES Anaplastic Large Cell Lymphoma (ALCL) 4 Acute Lymphocytic Leukemia (ALL) 4 Acute Myeloid Leukemia (AML) 4 Burkitt Lymphoma 4 Chronic Lymphocytic Leukemia (CLL) 5 Chronic Myelogenous Leukemia (CML) 5 Diffuse Large B-Cell Lymphoma (DLBCL) 6 follicular lymphoma (FL) 6 Lymphoma 7 MALT Lymphoma 7 Mantle Cell Lymphoma (MCL) 7 Myelodysplastic Syndrome (MDS) 8 Multiple Myeloma (MM) 8 Myeloproliferative Neoplasms (MPN) 8 Paroxysmal Nocturnal Hemoglobinuria (PNH) 9 SOLID TUMORS Bladder 9 Breast 9 Cervical 9 Colorectal (CRC) 9 Kidney 10 Melanoma 10 Non-Small Cell Lung Cancer (NSCLC) 10 Thyroid 10

2 Specimen Collection Specimen Retrieval Kits Supplies and containers for our laboratory services are permitted by State and Federal laws. CGI will provide you, at no charge, with all the supplies you need: requisition forms, tubes, packaging transport forms, etc. Supply requests can be submitted to us by contacting your account manager or by contacting our accessioning department. You can reach the department by phone at (888) or by Sending Your Specimens When you first sign up with CGI, your account representative will help you determine your specific courier needs, which are decided according to your geographical location. Our service runs both day and night, based upon our clients schedules, to ensure that our clients are able to continue to operate according to their own established schedule. FedEx is available for all clients outside of our local geographic region. Regardless of the method used, CGI will provide prompt and efficient service to ensure that clients receive results in a timely manner. Our accessioning office can be reached by phone (888) , or by Labeling Instructions Based on regulatory requirements, all specimen containers must be labeled with at least two patient identifiers such as, patient name and date of birth. Also, the collection dates and times must be on either the requisition or specimen container. All specimens received in the laboratory must have a completed requisition form with all appropriate information filled out, including: Patient name Patient DOB Collection data/time Specimen type/site Requesting physician 2

3 Bone Marrow Dry Tap Handling of a Bone Marrow Specimen Dry Tap CGI has a very high success rate with limited amounts of marrow as well as with more cellular aspirate specimens. The following specimen collection method can help our hemato-pathologists to reach a conclusive diagnosis on these types of specimens: 1. Collect 2 or more bone marrow core biopsies a. Make 5-10 touch imprint slides from the biopsies (for Cytology and ) Be sure to keep slides AWAY FROM FORMALIN Do not place open formalin jar anywhere near slides as the formalin fumes may affect the quality of morphologic evaluation Let all slides AIR DRY COMPLETELY before placing in the plastic container to prevent smudging b. Place the 1st bone marrow core biopsy in a Formalin jar (for Histology & IHC testing) c. Place the 2nd biopsy in RPMI media (for Flow Cytometry and/or Cytogenetics testing) Store in refrigerator until shipped d. Additional samples/clot should be submitted for histology 2. Indicate on REQUISITION that the specimen is a DRY TAP 3. Collect a peripheral blood specimen in a Sodium Heparin or green top tube (for possible Flow Cytometry and/or FISH testing, if indicated) 4. Collect a peripheral blood specimen in an EDTA or purple top tube (for possible molecular testing, if indicated) 5. Place each specimen in the Biohazard bag before placing in kit 6. Call or for a specimen pickup or contact your local account representative or client services if you have any questions. 3

4 Hematological Malignancies (ALCL - Burkitt Lymphoma) ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) ALCL FISH Panel ACUTE LYMPHOCYTIC LEUKEMIA (ALL) Myeloid/Lymphoid/Acute Leukemia Panel (Flow) B-ALL FISH Panel T-ALL FISH Panel ACUTE MYELOID LEUKEMIA (AML) Myeloid/Lymphoid/Acute Leukemia Panel (Flow) AML FISH Panel c-kit Mutation (Exon 8 & 17) CEBPA Mutation FLT3 Mutation NPM1 Mutation 2-8 C. BURKITT LYMPHOMA MYC/IGH DNA-FISH Probe 4

5 Hematological Malignancies (CLL, CML) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ZAP-70 Panel (Flow) CLL FISH Panel IGHV Mutation NOTCH1 Mutation SF3B1 Mutation TP53 Mutation MatBA -CLL/SLL CLL Complete 2-8 C. Peripheral Blood or Bone Marrow Aspirate: 1 lavender/edta tube with minimum 2-3 ml at FFPE: 3-5 FFPE sections at 10 μm thickness on regular slides at Peripheral Blood or Bone Marrow Aspirate: 1 lavender/edta tube with minimum 5-7 ml at FFPE: FFPE tissue block at room temp. or 0.5 cm3 fresh tissue in RPMI on ice. CHRONIC MYELOGENOUS LEUKEMIA (CML) Myeloid/Lymphoid/Acute Leukemia Panel (Flow) CML FISH Panel CML in Blast Crisis FISH Panel ABL Kinase Domain Mutation BCR/ABL Qualitative BCR/ABL Quantitative Major & Minor 1 Lavender/EDTA tube peripheral blood or bone marrow (3-5 ml) at room temperature or 2-8 C within 48 hours after collection. 5

6 Hematological Malignancies (Lymphoma) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) cmyc, Ki-67 (IHC) GCB vs. Non-GCB Subtyping (IHC) Lymphoid Panel (Flow) NHL FISH Panel B-Cell Clonality (IGH) TP53 Mutation MatBA -DLBCL DLBCL Complete SM 2-8 C or μm total FFPE sections at 2-8 C. FFPE: block containing 70% tumor. Minimum size: 2 mm x 2 mm tumor area, shipped at Fresh-Frozen Tissue: 0.2 cm3 minimum (in OCT is acceptable) containing 50% tumor. Stored at -80 C /-20 C, shipped on dry ice. Peripheral Blood or Bone Marrow Aspirate: 1 lavender/edta tube with minimum 5-7 ml at FFPE: FFPE tissue block at room temperature or 0.5 cm 3 fresh tissue in RPMI on ice. FOLLICULAR LYMPHOMA (FL) Lymphoid Panel (Flow) NHL FISH Panel MatBA -FL FFPE: block containing 70% tumor. Minimum size: 2 mm x 2 mm tumor area, shipped at Fresh-Frozen Tissue: 0.2 cm 3 minimum (in OCT is acceptable) containing 50% tumor. Stored at -80 C /-20 C, shipped on dry ice. 6

7 Hematological Malignancies (Lymphoma Continued) LYMPHOMA Lymphoid Panel (Flow) NHL FISH Panel B-Cell Clonality (IGH) T-Cell Clonality (TCRβ) T-Cell Clonality (TCRγ) MYD88 Mutation 2-8 C or μm total FFPE sections at 2-3 ml peripheral blood or bone marrow in an EDTA tube (Lavender-top). Specimen should be stored, transported at room temperature or 2-8 C. MALT LYMPHOMA Lymphoid Panel (Flow) NHL FISH Panel MANTLE CELL LYMPHOMA (MCL) Lymphoid Panel (Flow) NHL FISH Panel MatBA -MCL Peripheral Blood: minimum 3-5 ml, shipped at FFPE: block containing 60% tumor. Minimum size: 2 mm x 2 mm tumor area, shipped at Fresh-Frozen Tissue: 0.2 cm 3 minimum (in OCT is acceptable) containing 50% tumor. Stored at -80 C /-20 C, shipped on dry ice. 7

8 Hematological Malignancies (MDS, MM, MPN) MYELODYSPLASTIC SYNDROME (MDS) MDS FISH Panel MULTIPLE MYELOMA (MM) MM Panel (Flow) MM with PPC FISH Panel MYELOPROLIFERATIVE NEOPLASMS (MPN) Myeloid/Lymphoid/Acute Leukemia Panel (Flow) MPN FISH Panel ABL Kinase Domain Mutation BCR/ABL Quantitative Major & Minor CALR Mutation c-kit Mutation (D816) JAK2 Exon 12 Mutation JAK2 V617F Mutation MPL 515/505 Mutation MPN Complete SM 1 Lavender/EDTA tube peripheral blood or bone marrow (3-5 ml) at room temperature or 2-8 C within 48 hours after collection. 2-8 C. Peripheral Blood or Bone Marrow Aspirate: 1 lavender/edta tube with minimum 5-7 ml at room temperature or 2-8 C. FFPE: FFPE tissue block at 8

9 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PNH Test (Flow) Solid Tumors (Bladder, Breast, Cervical, Colorectal) BLADDER CANCER UroVysion ml urine in a suitable container. Same day shipping or PreservCyt should be used if the specimen will remain in transit for more than a day to ensure stability. BREAST CANCER PathVysion 3-5 µm thick FFPE sections on positively coated slides at Breast Complete SM CERVICAL CANCER FHACT Liquid cytology in PreservCyt or SurePath. Specimens should be sent within 3 weeks after collection. Specimens may be shipped at room temperature ( 25 C) but shipping at 4 C is recommended. Specimens shall not be frozen. Specimen volume recommended >10 ml. COLORECTAL CANCER (CRC) MMR Profile BRAF Mutation KRAS Mutation NRAS Mutation Micro-Satellite Instability PIK3CA Mutation CRC Complete SM FFPE Block or 3-5 FFPE sections at 10 μm thickness containing at least 20% of tumor cells on regular unstained slides at room temperature with H&E slides. Should contain both normal and tumor tissues from the same patient. Specimen contains over 20% of tumor cells FFPE tissue block or 3-5 FFPE sections at 10 μm thickness containing at least 20% of tumor cells on regular unstained slides at room temperature with H&E slides and 4-5 μm thick FFPE sections on positively coated slides at 9

10 Solid Tumors (Kidney, Melanoma, NSCLC, Thyroid) KIDNEY CANCER UroGenRA -Kidney Biopsy: minimum 3-4 needle/core biopsies (18-gauge needle) placed in a cryovial containing saline, transport frozen. (Minimum 70% tumor population). Resected Specimen: minimum of 0.2 cm 3 tissue, snap-frozen in a cryovial and transported in frozen condition. (Minimum 70% tumor population). MELANOMA BRAF Mutation BRAF cobas Mutation NRAS Mutation FFPE Block or 3-5 FFPE sections at 10 μm thickness containing at least 20% of tumor cells on regular unstained slides at room temperature with H&E slides. NON-SMALL CELL LUNG CANCER (NSCLC) ALK Break Apart DNA- FISH Probe ROS1 DNA-FISH Probe EGFR Mutation EGFR cobas Mutation KRAS Mutation Lung Complete SM 5 FFPE sections at 3-5 μm thickness on positively coated slides at FFPE Block or 3-5 FFPE sections at 10 μm thickness containing at least 20% of tumor cells on regular unstained slides at room temperature with H&E slides. FFPE tissue block or 3-5 FFPE sections at 10 μm thickness containing at least 20% of tumor cells and 5 FFPE sections at 3-5 μm thickness at THYROID CANCER BRAF Mutation NRAS Mutation FFPE Block or 3-5 FFPE sections at 10 μm thickness containing at least 20% of tumor cells on regular unstained slides at room temperature with H&E slides. v

Chromosomal analysis for prenatal samples, peripheral blood, bone marrow biopsy samples, various types of lymphomas, and solid tumors

Chromosomal analysis for prenatal samples, peripheral blood, bone marrow biopsy samples, various types of lymphomas, and solid tumors Chromosomal analysis for prenatal samples, peripheral blood, bone marrow biopsy samples, various types of lymphomas, and solid tumors FISH (fluorescence in situ hybridization) assays and many probes that

More information

Cancer. 9p21.3 deletion. t(12;21) t(15;17)

Cancer. 9p21.3 deletion. t(12;21) t(15;17) CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)

More information

Lymphoma Diagnostic Work-up from a Lab Perspective

Lymphoma Diagnostic Work-up from a Lab Perspective Lymphoma Diagnostic Work-up from a Lab Perspective Mohamed E. Salama M.D. Mohamed.salama@path.utah.edu Lymphoproliferative Disorders Malignant lymphoma 1. Non-Hodgkin lymphoma (NHL) 2. Hodgkin (disease)

More information

SPECIMEN SUBMISSION CHART Naples Pathology Associates

SPECIMEN SUBMISSION CHART Naples Pathology Associates For specimen collection instructions, see Client Services Manual SECTIONS: HISTOLOGY page 1 CYTOLOGY page 2 ADVANCED STUDIES page 4 NPA routine pickup: 263-1777 Immediate pickup (e.g. frozen section, lymphoma):

More information

WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED?

WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED? WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED? Which test should be submitted? The answer to this depends on the clinical signs, and the diagnostic question you are asking. If

More information

Please note: Contact Coppe Laboratories at 262-574-0701 if archival plasma samples need to be tested.

Please note: Contact Coppe Laboratories at 262-574-0701 if archival plasma samples need to be tested. Collecting a Coppe Laboratories Sample The Coppe Laboratories Sample Kit contains: Test Request Form (TRF) Heparin tube Absorbent sheet Biohazard bag Foil pouch Label for blood tube Box Seal Instructions

More information

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014 ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the

More information

Leukemias and Lymphomas: A primer

Leukemias and Lymphomas: A primer Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes

More information

HAEMATOLOGY LABORATORY

HAEMATOLOGY LABORATORY HAEMATOLOGY LABORATORY Head of Unit : Dr Raudhawati Osman Phone : +603-26155281 Email : raudhaosman@yahoo.com 1. INTRODUCTION The Haematology Unit, Department of Pathology, HKL provides tertiary diagnostic

More information

Classification Diagnostic Tools and Treatment of Non Hodgkin Lymphoma

Classification Diagnostic Tools and Treatment of Non Hodgkin Lymphoma Classification Diagnostic Tools and Treatment of Non Hodgkin Lymphoma American Society of Cytopathology 59 th Annual Scientific Meeting 2011 Douglas E. Gladstone, MD Clinical Director IPOP Associate Professor

More information

Specimen Collection Guide

Specimen Collection Guide Specimen Collection Guide Cytology General Guidelines Preservation Labeling Requisitions Slides Fixative Bottles Specimen Collection Guide Outline Gynecological Specimen Collection Guidelines Pap Pak conventional

More information

Understanding Lymphoma from a Lab Perspective Mohamed E. Salama M.D.

Understanding Lymphoma from a Lab Perspective Mohamed E. Salama M.D. Understanding Lymphoma from a Lab Perspective Mohamed E. Salama M.D. Medical Director, Hematopathology and Immunoperoxidase Staining ARUP Laboratories Lymphoproliferative Disorders Malignant lymphoma 1.

More information

MOLECULAR STUDIES IN THE PATHOLOGICAL DIAGNOSIS OF LYMPHOMA

MOLECULAR STUDIES IN THE PATHOLOGICAL DIAGNOSIS OF LYMPHOMA MOLECULAR STUDIES IN THE PATHOLOGICAL DIAGNOSIS OF LYMPHOMA CIQC/CAP-ACP SEMINAR DAVID LE BRUN DEPARTMENT OF PATHOLOGY AND MOLECULAR MEDICINE QUEEN S UNIVERSITY KINGSTON, ONTARIO This lecture aims to make

More information

March 19, 2014. Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith,

March 19, 2014. Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith, Dr. Daniel Duvall, Medical Officer Center for Medicare, Hospital and Ambulatory Policy Group Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244 Dr. Edith Hambrick,

More information

Malignant Lymphomas and Plasma Cell Myeloma

Malignant Lymphomas and Plasma Cell Myeloma Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations

More information

PROCUREMENT OF BONE MARROW SPECIMENS

PROCUREMENT OF BONE MARROW SPECIMENS Page 1 of 8 SITES AFFECTED _X Enterprise Chandler Good Samaritan PROCUREMENT OF BONE MARROW SPECIMENS A technologist at Chandler CORE and Samaritan are assigned to Bone Marrow duties Monday through Friday

More information

Supply and Re-order Form (Page 1 of 6)

Supply and Re-order Form (Page 1 of 6) Supply and Re-order Form (Page 1 of 6) MOLECULAR PATHOLOGY QTY UNITS SIZE DESCRIPTION STANDARD USE EXAMPLES 10/Box BD Affirm VPIII Microbial Identification Test Vaginitis Screening Gen-Probe Aptima Swab

More information

Part I: NCCN Practice Guidelines Tabular Summary (DD 3/20/13) PET and PET/CT

Part I: NCCN Practice Guidelines Tabular Summary (DD 3/20/13) PET and PET/CT Part I: NCCN Practice Guidelines Tabular Summary (DD 3/20/13) PET and NCCN guidelines were reviewed on 3/20/2013 for utilization of PET and (available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp).

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I LEUKEMIA FORMS CHAPTER 16A REVISED: SEPTEMBER 2016

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I LEUKEMIA FORMS CHAPTER 16A REVISED: SEPTEMBER 2016 LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer

More information

SEER SINQ s. Finalized March 2011

SEER SINQ s. Finalized March 2011 ized March 2011 : 20110067 First course treatment--heme & Lymphoid Neoplasms: Are the treatment guidelines in the "red book" still valid? See discussion. While I realize that the Hematopoietic Database

More information

Reference Range: 0.5-1.6 mmol/l (arterial) 0.7-2.1 mmol/l (venous) CPT Code: 83605

Reference Range: 0.5-1.6 mmol/l (arterial) 0.7-2.1 mmol/l (venous) CPT Code: 83605 LACTIC ACID Fasting, arterial specimen preferred. Please note whether arterial or venous. 0.5 ml heparinized plasma. Green top or PST must be drawn, placed on ice, and spun within 15 minutes. Immediately

More information

Clinical Information Systems to Support Personalized Medicine at the Bedside

Clinical Information Systems to Support Personalized Medicine at the Bedside Clinical Information Systems to Support Personalized Medicine at the Bedside March 2012 Mia Levy, MD, PhD Director Cancer Clinical Informatics, Vanderbilt Ingram Cancer Center Assistant Professor of Biomedical

More information

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:

More information

TABLE OF CONTENTS. Genoptix Medical Laboratory 2110 Rutherford Road Carlsbad, CA Phone: Fax:

TABLE OF CONTENTS. Genoptix Medical Laboratory 2110 Rutherford Road Carlsbad, CA Phone: Fax: TESTING DIRECTORY TABLE OF CONTENTS Genoptix Medical Laboratory 2110 Rutherford Road Carlsbad, CA 92008 Phone: 760.268.6200 Fax: 760.268.6201 Client Services Phone: 800.755.1605 Fax: 888.755.1604 CLIA

More information

CANCER GENETICS, INC.

CANCER GENETICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended

More information

CHG LAB SPECIMEN REQUIREMENTS FOR GENETIC TESTING: COLLECTION MANUAL

CHG LAB SPECIMEN REQUIREMENTS FOR GENETIC TESTING: COLLECTION MANUAL CHG LAB SPECIMEN REQUIREMENTS FOR GENETIC TESTING: Introduction COLLECTION MANUAL Successful chromosome analysis is dependent upon the receipt of satisfactory specimens. For all specimen types the following

More information

Non-Hodgkin s Lymphoma

Non-Hodgkin s Lymphoma Non-Hodgkin s Lymphoma Luis Fayad, MD Assistant Professor Clinical Medical Director Lymphoma/Myeloma Department Non-Hodgkin s Lymphoma Non-Hodgkin s lymphomas (NHL) are a heterogeneous group of malignant

More information

Extranodal Lymphomas. Anatomic Site 5/26/2011. How are extranodal lymphomas different? Importance of Anatomic Site in Diagnosing Extranodal Lymphoma

Extranodal Lymphomas. Anatomic Site 5/26/2011. How are extranodal lymphomas different? Importance of Anatomic Site in Diagnosing Extranodal Lymphoma How are extranodal lymphomas different? Extranodal Lymphomas Daniel A. Arber, MD Stanford University Many represent extranodal presentations of systemic disease Some are unique to specific anatomic sites

More information

Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA

Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA Interesting Case Review Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA History 63 y/o male with h/o CLL for 10 years Presents with worsening renal function and hypercalcemia

More information

ADx Bone Marrow Report. Patient Information Referring Physician Specimen Information

ADx Bone Marrow Report. Patient Information Referring Physician Specimen Information ADx Bone Marrow Report Patient Information Referring Physician Specimen Information Procedure: Reported: 01/14/2015 (203.00) Multiple myeloma; anemia, multiple lytic lesions; diagnosis of multiple myeloma

More information

Disease Response. Objectives

Disease Response. Objectives Disease Response Susan Barry, Clinical Trials Manager CALGB Statistical Center CRA Committee: New CRA Session 2010 Summer Group Meeting Objectives Review response criteria for solid tumor cancers, lymphomas,

More information

Genetic Testing - Oncology

Genetic Testing - Oncology Genetic Testing - Oncology I. Policy University Health Alliance (UHA) will reimburse for oncology genetic testing when they are determined to be medically necessary and when they meet the medical criteria

More information

Lymphoid proliferations: benign vs. malignant

Lymphoid proliferations: benign vs. malignant Lymphoid proliferations: benign vs. malignant Pathology Update - 16 th May 2014 Dr. Nikhil Sangle, M.D., FRCPath, FCAP Department of Pathology and Laboratory Medicine Staff Pathologist, London Health Sciences

More information

Molecular Stratification of Cancer in the

Molecular Stratification of Cancer in the Molecular Stratification of Cancer in the Clinical Setting David Gonzalez de Castro Molecular Diagnostics NHS FT and The Institute of Cancer Research, London, UK 1 2 The complexity of human cancer genomes

More information

Cytogenetic Testing in Acute Leukemia. June 4, 2009

Cytogenetic Testing in Acute Leukemia. June 4, 2009 Cytogenetic Testing in Acute Leukemia June 4, 2009 Objectives Describe genetic aspects of the 2008 WHO classification of acute leukemia Understand cytogenetic and molecular cytogenetic techniques Understand

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015 LEUKEMIA Response in Acute Myeloid Leukemia (AML) Response criteria in Acute Myeloid Leukemia for SWOG protocols is based on the review article Diagnosis and management of acute myeloid leukemia in adults:

More information

The Diagnosis of Cancer in the Pathology Laboratory

The Diagnosis of Cancer in the Pathology Laboratory The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens

More information

About B Cell Lymphomas Groupmeeting Klipp/Spang, December 09 2002 Dennis Kostka Max-Planck-Institute for Molecular Genetics Computational Molecular Biology Berlin 1 Overview Short History of Lymphoma Classification

More information

Abnormal reduction in all three cell lines Chronic disorder More than 6 months (no recommended definition) Excludes transient causes of pancytopenia

Abnormal reduction in all three cell lines Chronic disorder More than 6 months (no recommended definition) Excludes transient causes of pancytopenia André Tichelli Abnormal reduction in all three cell lines Chronic disorder More than 6 months (no recommended definition) Excludes transient causes of pancytopenia Particular situations of pancytopenia

More information

Updating the 2008 WHO Classification of Small B cell lymphomas Elias Campo

Updating the 2008 WHO Classification of Small B cell lymphomas Elias Campo Updating the 2008 WHO Classification of Small B cell lymphomas Elias Campo Hospital Clinic, University of Barcelona Barcelona, Spain Disclosure of Relevant Financial Relationships Dr. ELIAS CAMPO declares

More information

Myeloproliferative Neoplasm: Morphology, Molecular Updates and Cost-Effective Test Utilization 7/15/2015

Myeloproliferative Neoplasm: Morphology, Molecular Updates and Cost-Effective Test Utilization 7/15/2015 Welcome to Mayo Medical Laboratories Hot Topics. These presentations provide short discussion of current topics and may be helpful to you in your practice. Today our topic is Myeloproliferative Neoplasm:

More information

Fredrik.Enlund@gu.se Sahlgrenska universitetssjukhuset

Fredrik.Enlund@gu.se Sahlgrenska universitetssjukhuset Fredrik.Enlund@gu.se Sahlgrenska universitetssjukhuset 1 Techniques for sarcoma diagnostics Molecular Pathology of Solid Tumors Uppsala 120924 Klinisk Molekylär Patologi Klinisk Patologi och Cytologi Gene

More information

Acute leukemias and myeloproliferative neoplasms

Acute leukemias and myeloproliferative neoplasms Acute leukemias and myeloproliferative neoplasms GERGELY SZOMBATH SEMMELWEIS UNIVERSITY OF MEDICINE IIIRD. DEPARTMENT OF INTERNAL MEDICINE Basics of acute leukemia Neoplastic disease Cell of origin is

More information

Targeted Chemotherapy: Guiding patients to more personalized care

Targeted Chemotherapy: Guiding patients to more personalized care Targeted Chemotherapy: Guiding patients to more personalized care Anna Hitron, Pharm.D, MS, MBA, BCOP Oncology Pharmacy Specialist Baptist Health Louisville September 10, 2015 Objectives Discuss the role

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME II LYMPHOMA CHAPTER 9 REVISED: OCTOBER 2014

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME II LYMPHOMA CHAPTER 9 REVISED: OCTOBER 2014 Disease Information The two main malignant diseases of the lymphoreticular system are non-hodgkin's lymphoma and Hodgkin's disease. Lymphoma is a general term applied to a heterogeneous group of cancers

More information

Disorders of Hematopoietic System Lymphoproliferative Neoplasms

Disorders of Hematopoietic System Lymphoproliferative Neoplasms Disorders of Hematopoietic System Lymphoproliferative Neoplasms Vishala Neppalli, M.D Assistant Professor of Oncology, Hematopathology Roswell Park cancer Institute vishala.neppalli@roswellpark.org Learning

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

Advancing Therapies for Blood Cancers

Advancing Therapies for Blood Cancers Advancing Therapies for Blood Cancers Stuart L. Goldberg, MD Chief, Division of Leukemia John Theurer Cancer Center Hackensack University Medical Center Hackensack, NJ Associate Clinical Professor of Medicine

More information

Bone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital

Bone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital Bone Marrow Evaluation for Lymphoma Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital Indications One of the most common indications for a bone marrow biopsy is to evaluate for malignant lymphoma.

More information

Cytogenetics for the Rest of Us: A Primer

Cytogenetics for the Rest of Us: A Primer Cytogenetics for the Rest of Us: A Primer James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center Diane Maia, M.D. Pathologist, Bon Secours Hampton Roads Case #1 78 y.o. lady seen

More information

6/20/2014. PART I: Plasma Cell Myeloma. Plasma Cells

6/20/2014. PART I: Plasma Cell Myeloma. Plasma Cells MULTIPLE MYELOMA: THE TESTING, VALIDATION AND IMPLEMENTATION OF CELL SEPARATION TECHNOLOGY FOR IMPROVED PATIENT CARE Elizabeth Harper CG(ASCP), Binh Vo CG(ASCP), Joey Pena CG(ASCP), Denise Lovshe CG(ASCP),

More information

Pathology No: SHS-CASE No. Date of Procedure: Client Name Address

Pathology No: SHS-CASE No. Date of Procedure: Client Name Address TEL #: (650) 725-5604 FAX #: (650) 725-7409 Med. Rec. No.: Date of Procedure: Sex: A ge: Date Received: Date of Birth: Account No.: Physician(s): Client Name Address SPECIMEN SUBMITTED: LEFT PIC BONE MARROW,

More information

Collect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.

Collect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge. Complete Blood Count CPT Code: CBC with Differential: 85025 CBC without Differential: 85027 Order Code: CBC with Differential: C915 Includes: White blood cell, Red blood cell, Hematocrit, Hemoglobin, MCV,

More information

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010) MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.

More information

Cytology Sample Collection and Transport

Cytology Sample Collection and Transport Cytology Sample Collection and Transport Gynecologic Cytology Collection Patient Preparation The optimal time for collection of the Pap smear is two weeks after the first day of the last menstrual period.

More information

information for payers and referrers

information for payers and referrers a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m information for payers and referrers Spring 2014 For more information, visit www.dfbwcc.org/bmt. o u r expertise Since its founding in

More information

Oncology Best Practice Documentation

Oncology Best Practice Documentation Oncology Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Solid Tumors Lymphomas Leukemias Myelodysplastic Syndrome Pathology Findings

More information

Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY

Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular

More information

Office Procedure & Specimen Collection Manual

Office Procedure & Specimen Collection Manual Office Procedure & Specimen Collection Manual Table of Contents Table of Contents... 2 Overview of Services... 4 Mission Statement... 4 Testing Services Offered... 4 Ancillary Services... 4 Customer Service...

More information

Genomic Medicine Education Initiatives of the College of American Pathologists

Genomic Medicine Education Initiatives of the College of American Pathologists Genomic Medicine Education Initiatives of the College of American Pathologists Debra G.B. Leonard, MD, PhD, FCAP Chair, Personalized Healthcare Committee, CAP Professor of Pathology, Weill Cornell Medical

More information

Acute Leukemia - D Savage - 8 January chronic leukemia lymphoma myeloma. differentiated

Acute Leukemia - D Savage - 8 January chronic leukemia lymphoma myeloma. differentiated Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2 13 82 3 82

More information

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div. Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under

More information

MEDICAL COVERAGE POLICY

MEDICAL COVERAGE POLICY Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each

More information

Non-Hodgkin Lymphoma Luciano J. Costa MD, PhD

Non-Hodgkin Lymphoma Luciano J. Costa MD, PhD Non-Hodgkin Lymphoma Luciano J. Costa MD, PhD Assistant Professor Department of Medicine Division of Hematology and Oncology Medical University of South Carolina Objectives Discuss the molecular basis

More information

CAR T cell therapy for lymphomas

CAR T cell therapy for lymphomas CAR T cell therapy for lymphomas Sattva S. Neelapu, MD Associate Professor and Deputy Chair ad interim Department of Lymphoma and Myeloma UT MD Anderson Cancer Center, Houston, TX CAR T cell therapy What

More information

IMMEDIATE HOT LINE: Effective March 2, 2015

IMMEDIATE HOT LINE: Effective March 2, 2015 MEDICARE COVERAGE OF LABORATORY TESTING Please remember when ordering laboratory tests that are billed to Medicare/Medicaid or other federally funded programs, the following requirements apply: 1. Only

More information

Genomic Analysis of Mature B-cell Malignancies

Genomic Analysis of Mature B-cell Malignancies Genomic Analysis of Mature B-cell Malignancies Update and Lessons Learned Omar Abdel-Wahab, MD Memorial Sloan Kettering Cancer Center Human Oncology and Pathogenesis Program and Leukemia Service Disclaimer:

More information

Approaching Pancytopenia

Approaching Pancytopenia Approaching Pancytopenia Lisa Sproat MD, MSW American College of Osteopathic Internists Annual Convention 2013 2012 MFMER slide-1 Objectives Understand work up of Pancytopenia Present differential diagnosis

More information

Chronic Myeloid Leukemia (CML) Matt Walter Markey Program October 21, 2014

Chronic Myeloid Leukemia (CML) Matt Walter Markey Program October 21, 2014 Chronic Myeloid Leukemia (CML) Matt Walter Markey Program October 21, 2014 CML: paradigm for cancer treatment Identify primary genetic abnormality Develop an agent that targets that abnormality Monitor

More information

Acute Leukemia - D Savage - 8 January differentiated. chronic leukemia lymphoma myeloma. Total WBC > 60. Blast Pro Myel Meta Band Seg Lymph

Acute Leukemia - D Savage - 8 January differentiated. chronic leukemia lymphoma myeloma. Total WBC > 60. Blast Pro Myel Meta Band Seg Lymph Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2 13 82 3 82

More information

Lymphoplasmacytic Lymphoma. Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH

Lymphoplasmacytic Lymphoma. Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH Lymphoplasmacytic Lymphoma versus IGM Multiple Myeloma Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH Hematology consult patient 48 yo woman presents to ER with nonspecific complaints:

More information

A23: Oncologic Disease- Tumor Markers

A23: Oncologic Disease- Tumor Markers A23: Oncologic Disease- Tumor Markers Diagnosis Tumor Markers and Genetic Markers Use for Specific Malignancy The following information is from multiple guideline sources as recommendations for use of

More information

ASCP RESIDENT REVIEW COURSE Ricardo Valdez, MD Lymphoma Study Questions

ASCP RESIDENT REVIEW COURSE Ricardo Valdez, MD Lymphoma Study Questions ASCP RESIDENT REVIEW COURSE Ricardo Valdez, MD Lymphoma Study Questions 1. Which of the following is most likely to involve multiple lymph node groups, visceral organs, bone marrow, and peripheral blood

More information

Specimen Collection Manual

Specimen Collection Manual Specimen Collection Manual Poplar Healthcare September 20, 2014 V.1.2 Contents General Information:... 3 About Poplar Healthcare:... 3 Address:... 3 Website:... 3 Phone Number:... 3 Fax Number:... 3 Client

More information

Immunohistochemical classification of malignant lymphomas

Immunohistochemical classification of malignant lymphomas Immunohistochemical classification of malignant lymphomas Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Thanks to Jan Klos Important issues Distinction from non-hematopoietic neoplasms

More information

Acute myeloid leukemia (AML)

Acute myeloid leukemia (AML) Acute myeloid leukemia (AML) Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult

More information

Flow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma

Flow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma Flow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma Maryalice Stetler-Stevenson, M.D., Ph.D. Flow Cytometry Unit, Laboratory of Pathology, DCS, NCI,NIH DEPARTMENT OF HEALTH & HUMAN SERVICES

More information

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including

More information

Second Cancers in Adults

Second Cancers in Adults Second Cancers in Adults This document focuses on second cancers in adults. For information about second cancers after treatment of childhood cancers, see our document Children Diagnosed With Cancer: Late

More information

For patients with chronic myeloid leukemia ELECTRONIC MEDICAL DIARY

For patients with chronic myeloid leukemia ELECTRONIC MEDICAL DIARY The Chronic Myelogenous Leukemia Society of Canada La Société de la Leucemie Myéloide chronique du Canada ELECTRONIC MEDICAL DIARY For patients with chronic myeloid leukemia INTRODUCTION This electronic

More information

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)

More information

Diffuse Large B-cell Lymphoma, Burkitt Lymphoma and the Gray Zone. Relative Frequency of B-cell NHL. Diffuse Large B-cell Lymphoma Definition

Diffuse Large B-cell Lymphoma, Burkitt Lymphoma and the Gray Zone. Relative Frequency of B-cell NHL. Diffuse Large B-cell Lymphoma Definition Diffuse Large B-cell Lymphoma, Burkitt Lymphoma and the Gray Zone L. Jeffrey Medeiros, M.D. M.D. Anderson Cancer Center Relative Frequency of B-cell NHL Diffuse large B-cell lymphoma 37 % Follicular lymphoma

More information

Role of Immunoglobulin Gene Expression in Acute Myeloid Leukemia

Role of Immunoglobulin Gene Expression in Acute Myeloid Leukemia Role of Immunoglobulin Gene Expression in Acute Myeloid Leukemia C. Cameron Yin, MD, PhD Department of Hematopathology University of Texas MD Anderson Cancer Center Immunoglobulin (Ig) has been presumed

More information

For years, drug developers have used histology as the

For years, drug developers have used histology as the NOVEL Clinical Trial Designs in oncology: An Histology-Independent Approach Cancer s heterogeneity is a leading reason why product development in this therapeutic area is so risky and costly and why the

More information

targeted therapy a guide for the patient

targeted therapy a guide for the patient targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting

More information

CANCER GENETICS, INC. (Exact name of registrant as specified in its charter)

CANCER GENETICS, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended

More information

Subtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand.

Subtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand. 1 2 3 4 The FAB assigns a cut off of 30% blasts to define AML and relies predominantly on morphology and cytochemical stains (MPO, Sudan Black, and NSE which will be discussed later). Subtypes of AML follow

More information

Flow cytometric approach to the diagnosis and classification of mature B-cell lymphoid neoplasm 가천의대길병원진단검사의학과 안정열

Flow cytometric approach to the diagnosis and classification of mature B-cell lymphoid neoplasm 가천의대길병원진단검사의학과 안정열 Flow cytometric approach to the diagnosis and classification of mature B-cell lymphoid neoplasm 가천의대길병원진단검사의학과 안정열 Mature B-cell neoplasm 1. Mature B-cell : SIg(+) & lack of Ags of immaturity (TdT, CD34)

More information

Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.

Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D. Chronic Lymphocytic Leukemia AAIM Triennial October 2012 Susan Sokoloski, M.D. Case Study 57 year old male, trial application for $1,000,000 Universal Life coverage Cover letter from sales agent indicates

More information

Guidelines for Handling and Shipping of Blood Samples

Guidelines for Handling and Shipping of Blood Samples Biofocus Institute for Laboratory Medicine Dr. med. Doris Bachg Dr. med. Uwe Haselhorst Berghäuser Str. 295 45659 Recklinghausen Germany contact: Dr. Doris Bachg (bachg@biofocus.de) phone +49 2361 3000-144

More information

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking Q1/2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties

More information

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational

More information

Mayo Study of Lymphoma and Leukemia

Mayo Study of Lymphoma and Leukemia Mayo Study of Lymphoma and Leukemia Clinic Controls Mayo Study of Lymphoma and Leukemia (Clinic Controls) Who is Participating in this Study? Patients coming to Mayo Clinic who have never been diagnosed

More information

Stem Cell Transplantation

Stem Cell Transplantation Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance

More information

Non Hodgkin Lymphoma:

Non Hodgkin Lymphoma: Non Hodgkin Lymphoma: Non Hodgkin Lymphoma, often referred to as NHL, is a cancer originating in the lymphocytes, a type of blood cell, which are integral to the body s immune system. Non Hodgkin Lymphoma

More information

Main Street Planning Group 180 East Main Street Suite 110 Patchogue, NY 11772 Tel: 631.647.4694 Fax: 631.647.4697 MainStreetPlanningGroup.

Main Street Planning Group 180 East Main Street Suite 110 Patchogue, NY 11772 Tel: 631.647.4694 Fax: 631.647.4697 MainStreetPlanningGroup. Main Street Planning Group 180 East Main Street Suite 110 Patchogue, NY 11772 Tel: 631.647.4694 Fax: 631.647.4697 MainStreetPlanningGroup.com Presented by Ted Mageau Ted@MainStreetPlanningGroup.com Life

More information

CancerTREATMENT NGS+ NSCLC Summary Report Page 1 of 7 PATIENT SPECIMEN PHYSICIAN

CancerTREATMENT NGS+ NSCLC Summary Report Page 1 of 7 PATIENT SPECIMEN PHYSICIAN Page 1 of 7 POSITIVE TEST RESULTS Biomarker Result DETECTED NEGATIVE TEST RESULTS FDA Approved Therapies Targeting Molecular Pathway TEST DESCRIPTION: CancerTREATMENT NGS+ uses Next Generation Sequencing

More information

Common Cancers & Hereditary Syndromes

Common Cancers & Hereditary Syndromes Common Cancers & Hereditary Syndromes Elizabeth Hoodfar, MS, LCGC Regional Cancer Genetics Coordinator Kaiser Permanente Northern California Detect clinical characteristics of hereditary cancer syndromes.

More information

Watch and wait Monitoring while treatment is not necessary

Watch and wait Monitoring while treatment is not necessary Watch and wait Monitoring while treatment is not necessary Revised December 2011 The diagnosis of a blood cancer can be a devastating event for patients, families and friends. It is therefore vital for

More information

Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms

Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms Clin Lab Med 27 (2007) 487 512 Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms Fiona E. Craig, MD Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine,

More information